No robust randomised controlled trial of a chemically verified BPC-157 plus Ac-LKKTETQ TB-500 formulation was identified in the literature reviewed for this article
Here's how they compare: Peptide Primary research area FDA status Advisory committee review BPC-157 Tissue repair, angiogenesis Not approved Yes (free base + acetate) TB-500 Actin regulation, cell migration Not approved Yes MOTS-c Mitochondrial metabolism Not approved Yes KPV Anti-inflammatory Not approved Yes GHK-Cu Copper-peptide skin/healing Not approved Not on 2026 agenda For a deeper comparison of BPC-157 and its most-researched counterpart, see our BPC-157 vs TB-500 research comparison
Common Peptides Used With TRT Who Benefits From a Peptides and Testosterone Stack
However, data on oral bioavailability is limited and may vary greatly depending on formulation
Unlike some peptides that require cycling to prevent receptor desensitization, AOD-9604 does not appear to lose efficacy with continuous use based on available data
Baseline measurements before starting, periodic monitoring during use, and follow-up assessment after cycling off provide data points that can reveal individual response patterns
